Aptus Capital Advisors LLC Takes $1.62 Million Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Aptus Capital Advisors LLC acquired a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 139,278 shares of the company's stock, valued at approximately $1,624,000. Aptus Capital Advisors LLC owned 0.14% of Intellia Therapeutics as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in NTLA. PDT Partners LLC grew its stake in shares of Intellia Therapeutics by 2,111.5% in the fourth quarter. PDT Partners LLC now owns 327,608 shares of the company's stock valued at $3,820,000 after buying an additional 312,794 shares in the last quarter. Schonfeld Strategic Advisors LLC grew its position in Intellia Therapeutics by 7.6% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 145,502 shares of the company's stock valued at $1,697,000 after acquiring an additional 10,223 shares in the last quarter. Northern Trust Corp increased its stake in Intellia Therapeutics by 13.0% during the fourth quarter. Northern Trust Corp now owns 979,137 shares of the company's stock worth $11,417,000 after purchasing an additional 112,847 shares during the period. Aquatic Capital Management LLC lifted its position in shares of Intellia Therapeutics by 98.7% during the fourth quarter. Aquatic Capital Management LLC now owns 182,434 shares of the company's stock worth $2,127,000 after purchasing an additional 90,634 shares in the last quarter. Finally, Virtus ETF Advisers LLC boosted its stake in shares of Intellia Therapeutics by 47.7% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,242 shares of the company's stock valued at $61,000 after purchasing an additional 1,692 shares during the period. Institutional investors and hedge funds own 88.77% of the company's stock.

Analyst Ratings Changes

A number of research firms have issued reports on NTLA. Barclays reduced their target price on shares of Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Morgan Stanley lowered Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and decreased their target price for the company from $56.00 to $11.00 in a report on Monday, January 27th. HC Wainwright initiated coverage on Intellia Therapeutics in a report on Wednesday, March 5th. They set a "buy" rating and a $30.00 price target on the stock. StockNews.com upgraded Intellia Therapeutics to a "sell" rating in a research note on Monday, March 3rd. Finally, Citigroup lifted their price target on shares of Intellia Therapeutics from $12.00 to $14.00 and gave the stock a "neutral" rating in a research note on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $36.68.

Intellia Therapeutics Price Performance

NTLA stock opened at $8.44 on Tuesday. Intellia Therapeutics, Inc. has a 12 month low of $5.90 and a 12 month high of $28.18. The company has a market cap of $874.24 million, a price-to-earnings ratio of -1.55 and a beta of 2.33. The company has a fifty day moving average price of $8.30 and a 200 day moving average price of $11.29.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.